Stem Cell Therapeutics Announces Issuance of Third US Patent
"I am greatly encouraged by the issuance of this patent, as it claims the concept of a combined approach to successful regeneration of brain tissue" said Dr. Joseph Tucker, President and CEO of Stem Cell Therapeutics. "The need to both increase the number of neural stem cells and induce their differentiation to appropriate cell types is likely to be a key step in a variety of stem cell based approaches to the treatment of neurological disorders".
Exploiting the capacity of neural stem cells to regenerate lost or dysfunctional brain tissue is one of the most potent therapeutic strategies currently in clinical development. A significant challenge faced by developers of such clinical approaches is that a substantial expansion in stem cell number needs to occur that is coupled with a directed differentiation of those stem cells to appropriate cell types. In the absence of meeting both requirements, a stem cell based therapy may suffer from reduced effectiveness.
The new patent describes methods to enhance the formation of neuronal or glial precursor cells from neural stem cells. U.S. Patent 7,048,934 is the third patent to issue to Stem Cell Therapeutics from an intellectual property estate that includes more than 35 pending applications filed worldwide.
Topics
Organizations
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.